Supplementary Appendix
|
|
- Jonas Joseph
- 5 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in glioblastomas. N Engl J Med 2;364: DOI:.56/NEJMoa632.
2
3 TUMOR SAMPLES AND PATIENTS
4 CELL LINES AND CELL CULTURE
5 GENOMIC DNA PREPARATION GENOMIC DATA PRE-PROCESSING COPY NUMBER VARIATION ANALYSIS
6 MUTATIONAL ANALYSES
7 REAL-TIME POLYMERASE CHAIN REACTION RETROVIRAL INFECTION AND EGF STIMULATION μ μ μ
8 PROTEIN EXTRACTION AND IMMUNOBLOTTING CELL VIABILITY ASSAY μ μ CELL CYCLE ANALYSIS CELLULAR SENESCENCE ASSAY
9 WOUND HEALING ASSAY SOFT AGAR ASSAY APOPTOSIS ASSAYS μ μ
10 STATISTICS
11
12 75 Glioblastomas of Study Set NFKBIA gene expression (log2r/g) 2 3 p =.9 NFKBIA wt/egfr wt NFKBIA del only EGFR + only NFKBIA del/egfr + Linear regression LOWESS smooth fit EGFR gene expression (log2r/g) Suppl. Figure. Relationship between NFKBIA and EGFR Expression in Glioblastoma. Linear regression of EGFR gene expression on NFKBIA gene expression in 75 glioblastomas of Study Set indicates a statistically significant relationship between both transcripts in 75 glioblastomas of Study Set : tumors with diminished NFKIBA expression due to gene deletion (del) have comparatively low EGFR expression, and tumors with high EGFR expression due to gene amplification (+) have intact NFKBIA expression. Gene expression values are expressed as log2r/g ratios estimated by the RMA pre-processing algorithm. Locally weighted least squares (LOWESS) smooth fit confirmed the appropriateness of a linear regression analysis.
13 U8 U87 LN229 ctrl ctrl NFKBIA+ ctrl NFKBIA+ NFKBIA+ ectopic endog. NFKBIA Flag α-tubulin NFKBIA protein (%) U8 U87 LN229 ctrl NFKBIA+ Suppl. Figure 2. Retroviral Expression of NFKBIA in Human Glioblastoma Cells. Endogenous (ctrl) and ectopic (FLAG-tagged) NFKBIA protein expression assessed by immunoblotting in three glioblastoma cell lines (U8, U87, and LN229) with heterozygous NFKBIA deletions retrovirally transduced with NFKBIA (NFKBIA+).
14 A B p =.4 p =.35 C U87-ctrl Debris Dip G: 39.% Dip G2: 3.9% Dip S: 47.% U87-NFKBIA+ Debris Dip G: 62.9% Dip G2: 9.6% Dip S: 27.6% D Cell viability (normal. to øctrl) Cell viability (normal. to øwt) U8-ctrl U8-NFKBIA U87-ctrl U87-NFKBIA+ (5%) LN229-ctrl LN229-NFKBIA+ U87-ctrl U87-NFKBIA+ Debris Dip G: 54.5% Dip G2: 26.% Dip S: 9.5% Debris Dip G: 62.% Dip G2: 22.2% Dip S: 5.8% (5%) E U87-ctrl U87-NFKBIA+ F U87-ctrl U8-ctrl U87-NFKBIA+ U8-NFKBIA+ % soft agar colony 2 p = LN229-ctrl U8-ctrl LN229-NFKBIA+ U8-NFKBIA+ U8-ctrl LN229-ctrl U8-NFKBIA+ LN229-NFKBIA+ % soft agar colony % soft agar colony p =.2 p =. Suppl. Figure 3. NFKBIA Functions as a Tumor Suppressor in Glioblastomas. (A) Retroviral re-expression of NFKBIA (NFKBIA+) in glioblastoma cells decreases cell proliferation and foci formation in culture and induces a vacuolated, senescence-like phenotype, compared to control (ctrl) cells. (B) NFKBIA re-expression decreases glioblastoma cell viability (mean ± SE) as measured spectrophotometrically via bioreduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye by dehydrogenase enzymes of metabolically active cells. p values according to unpaired t-test. (C) NFKBIA reexpression induces accumulation of cells in G/G and reduction of the transition from the G2 to the S phase of the cell cycle. (D) NFKBIA re-expression induces cellular senescence, as indicated by expression of senescence-associated β-galactosidase (SA-β-gal) (green); percentage of positively staining cells in a broader view indicated in parentheses. (E) NFKBIA re-rexpression reduces the migratory potential of glioblastoma cells, as assessed by a wound healing assay. (F) NFKBIA re-expression constrains the tumorigenic potential of glioblastoma cells, as measured by colony formation in soft agar (mean ± SE). p values according to unpaired t-test.
15 A C Cell viability (normal. to øwt) U87-ctrl p =. U87-ctrl (TMZ) p =.7 U87-NFKBIA+ (TMZ) B U8-ctrl U8 (TMZ) U8-NFKBIA+ (TMZ) U87-ctrl (TMZ) U87-NFKBIA+ (TMZ) LN229-ctrl (TMZ) LN229-NFKBIA+ (TMZ) viable cells late stage 3.% 4 viable cells 9.44% 4 viable cells.95% 4 viable cells 5.85% all cells all cells all cells all cells FL3 Log 2 FL3 Log 2 FL3 Log 2 FL3 Log FL Log early stage 5.% FL Log.4% FL Log 2.55% FL Log 9.35% Suppl. Figure 4. NFKBIA Sensitizes Glioblastoma Cells to Temozolomide. (A) Cell viability (mean ± SE) in mock (plain media)-treated U87 control (ctrl) cells, TMZ-treated U87 cells, and TMZ-treated U87 cells re-expressing NFKBIA (NFKBIA+), based on bioreduction of MTT dye by dehydrogenase enzymes of metabolically active cells. p values according to unpaired t-test. (B) Fluorescence microscopy and Hoechst staining of mock- and TMZ-treated U8-ctrl and U8-NFKBIA+ cells. Arrows: Nuclear chromatin condensation (pyknosis) indicates early apoptosis. (C) Flow cytometry analysis for early and late stages of apoptosis based on annexin V and propidium iodide staining in TMZ-treated U87-ctrl vs. U87-NFKBIA+ cells and LN229-ctrl vs. LN229-NFKBIA+ cells.
16 A 47 Glioblastomas of Study Set 8 Probability of Survival NFKBIA high NFKBIA low Log-rank p =.5 B 9 Glioblastomas of Study Set 9 Probability of Survival Log-rank p =. NFKBIA high NFKBIA low No. at Risk Time (weeks) No. at Risk Time (weeks) Suppl. Figure 5. NFKBIA Expression Associated with Glioblastoma Outcome. Kaplan-Meier estimated survival functions for 47 glioblastoma patients of Study Set 8 (A) and for 9 patients of Study Set 9 (B). In both sets, patients were stratified according to median NFKBIA expression. Patients with tumors having high vs. low NFKBIA expression had estimated median survival durations of 8 vs. 32 weeks in Study Set 8 and estimated median survival durations of 77 vs. 5 weeks in Study Set 9 (see main text for corresponding Cox model statistics). Small vertical lines across the curves indicate patients who were alive at last follow-up. The numbers at risk refer to the numbers of patients at risk entering each indicated time interval. p values according to log-rank test.
17 22 Malignant gliomas of Study Set 7 NFKBIA expression (R/G x^3) p =.2 p >.5 p >.5 Probability of Survival NFKBIA Pri-high NFKBIA Pri-low Log-rank p =.2 Pri Rec (NFKBIA high) Pri Rec (NFKBIA low). No. at Risk Time (weeks) Suppl. Figure 6. NFKBIA Expression in Initial and Recurrent Tumor. Expression of NFKBIA in 22 matched malignant glioma pairs from primary (Pri) and recurrent (Rec) disease in Study Set 7 and corresponding estimates of overall survival for the patients with high vs. low ( vs. ) NFKBIA abundance at initial disease (left panel) indicate the survival significance of NFKBIA status at initial diagnosis in these patients. Gene expression values indicate the ratio of red (R, Cy5) to green (G, Cy3) fluorescence dye intensity values. Box plots depict the smallest and largest observations (upper and lower whiskers, respectively), interquartile range (IQR, box), and median (white line). Data observations more than.5 IQR lower than the first quartile or.5 IQR higher than the third quartile were considered as outliers. Subgroups in the left panel according to median NFKBIA abundance (Pri-high vs. Pri-low) in primary disease. Significant downregulation of NFKBIA in the recurrent disease of tumors with initially high expression (p =.2, Wilcoxon signed-rank test) implies that loss of NFKBIA could be a molecular feature associated with disease progression. Small vertical lines across the curves in the right panel indicate patients who were alive at last follow-up. The numbers at risk refer to the numbers of patients at risk entering each indicated time interval. p values according to log-rank test.
18 A 29 Glioblastomas of Study Set 7 B. MGMT high-risk/nfkbia high MGMT high-risk/nfkbia low.8 28 Glioblastomas of Study Set 8..8 MGMT high-risk/nfkbia high MGMT high-risk/nfkbia low Probability of Survival.6.4 Log-rank p =.3 Probability of Survival.6.4 Log-rank p = No. at Risk Time (weeks) No. at Risk Time (weeks) C 4 Glioblastomas of Study Set 9 D. MGMT high-risk/nfkbia high MGMT high-risk/nfkbia low.8 2 Glioblastomas of Study Set treated with TMZ/RT..8 MGMT unmethyl./nfkbia high MGMT unmethyl./nfkbia low Probability of Survival.6.4 Log-rank p =.8 Probability of Survival.6.4 Log-rank p = No. at Risk Time (weeks) No. at Risk Time (weeks) 25 Suppl. Figure 7. Survival Association for NFKBIA in MGMT High-Risk Glioblastomas. Kaplan-Meier estimates of overall survival in glioblastoma patients of Study Sets 7, 8, 9, and. Small vertical lines across the curves indicate patients who were alive at last follow-up. The numbers at risk refer to the number of patients at risk entering each indicated time interval. p values according to log-rank test. (A) Estimated survival function for the instance of likely unmethylated MGMT gene promoter status (6% of tumors with highest MGMT expression) with high-risk for unfavorable disease in 29 glioblastomas of Study Set 7, separated into two groups according to median NFKBIA expression (see main text for corresponding Cox model statistic). (B) Survival estimates for a similar model in 28 glioblastomas of Study Set 8 (Cox model HR:.47, 95%-CI: for high vs. low NFKBIA expression). Estimated median durations of survival for high vs. low NFKBIA expression were 53 vs weeks. (C) Survival estimates for a similar model in 4 glioblastomas of Study Set 9 (Cox model HR:.63, 95%-CI: for high vs. low NFKBIA expression). Estimated median durations of survival for high vs. low NFKBIA expression were 59 vs. 44 weeks. (D) Survival estimates for 2 newly diagnosed glioblastoma patients of Study Set with unmethylated MGMT gene promoter status and treated with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), stratified according to median NFKBIA expression (see main text for corresponding Cox model statistic).
19 A 9 Glioblastomas of Study Set 9 B 74 Glioblastomas of Study Set..8 NFKBIA/MGMT low-risk NFKBIA/MGMT intermediate-risk NFKBIA/MGMT high-risk..8 NFKBIA/MGMT low-risk NFKBIA/MGMT intermediate-risk NFKBIA/MGMT high-risk Probability of Survival.6.4 Log-rank p =.6 Probability of Survival.6.4 Log-rank p = No. at Risk Time (weeks) No. at Risk Time (weeks) Suppl. Figure 8. Combined NFKBIA/MGMT Predictor Model in Glioblastoma. Combined NFKBIA/MGMT risk group models in 9 glioblastomas of Study Set 9 (Panel A) and in 74 glioblastoma patients of Study Set (Panel B). Assignment of patients to low, moderate, and high-risk groups is based on NFKBIA expression (dichotomized at the median) and MGMT status (MGMT expression dichotomized at the median or based on MGMT gene promoter methylation). Higher-than-median NFKBIA expression and lower-thanmedian MGMT expression denotes a low-risk group in Panel A, as does higher-than-median NFKBIA expression and methylated MGMT promoter status in Panel B; lower-than-median NFKBIA expression and higher-than-median MGMT expression denotes a high-risk group in Panel A, as does lower-than-median NFKBIA expression and unmethylated MGMT promoter status in panel B; all other cases were assigned to an intermediate risk group. Small vertical lines across the curves indicate patients who were alive at last follow-up. The numbers at risk refer to the numbers of patients at risk entering each indicated time interval. p values according to log-rank test.
Nature Genetics: doi: /ng.2995
Supplementary Figure 1 Kaplan-Meier survival curves of patients with brainstem tumors. (a) Comparison of patients with PPM1D mutation versus wild-type PPM1D. (b) Comparison of patients with PPM1D mutation
More informationNFKBIA Deletion in Glioblastomas
original article NFKBIA Deletion in Glioblastomas Markus Bredel, M.D., Ph.D., Denise M. Scholtens, Ph.D., Ajay K. Yadav, Ph.D., Angel A. Alvarez, B.Sc., Jaclyn J. Renfrow, M.A., James P. Chandler, M.D.,
More informationNature Genetics: doi: /ng Supplementary Figure 1. Details of sequencing analysis.
Supplementary Figure 1 Details of sequencing analysis. (a) Flow chart showing which patients fall into each category and were used for analysis. (b) Graph showing the average and median coverage for all
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationgliomas. Fetal brain expected who each low-
Supplementary Figure S1. Grade-specificity aberrant expression of HOXA genes in gliomas. (A) Representative RT-PCR analyses of HOXA gene expression in human astrocytomas. Exemplified glioma samples include
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationSupplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier
Supplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) in a cohort of patients (N=52) with stage III primary ovarian
More informationNature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from
Supplementary Figure 1 SEER data for male and female cancer incidence from 1975 2013. (a,b) Incidence rates of oral cavity and pharynx cancer (a) and leukemia (b) are plotted, grouped by males (blue),
More informationSupplementary Materials
Supplementary Materials Figure S1. MTT Cell viability assay. To measure the cytotoxic potential of the oxidative treatment, the MTT [3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide] assay
More informationNature Neuroscience: doi: /nn Supplementary Figure 1
Supplementary Figure 1 EGFR inhibition activates signaling pathways (a-b) EGFR inhibition activates signaling pathways (a) U251EGFR cells were treated with erlotinib (1µM) for the indicated times followed
More informationSupplementary Figure 1. The CagA-dependent wound healing or transwell migration of gastric cancer cell. AGS cells transfected with vector control or
Supplementary Figure 1. The CagA-dependent wound healing or transwell migration of gastric cancer cell. AGS cells transfected with vector control or 3xflag-CagA expression vector were wounded using a pipette
More informationSupplementary Information
Supplementary Information Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma Tomohiro Yamaki, Yusuke Suenaga, Toshihiko Iuchi, Jennifer Alagu, Atsushi Takatori,
More informationCancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results. Madrid, March 2015
1 Cancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results Madrid, March 2015 2 Cancer Treatments Surgical - whenever possible, Effective mostly in Early stages,
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationFile Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables. File Name: Peer Review File Description:
File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables File Name: Peer Review File Description: Primer Name Sequence (5'-3') AT ( C) RT-PCR USP21 F 5'-TTCCCATGGCTCCTTCCACATGAT-3'
More informationSupplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade
Cancer Cell, Volume 33 Supplemental Information Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial Alan Mackay,
More informationp.r623c p.p976l p.d2847fs p.t2671 p.d2847fs p.r2922w p.r2370h p.c1201y p.a868v p.s952* RING_C BP PHD Cbp HAT_KAT11
ARID2 p.r623c KMT2D p.v650fs p.p976l p.r2922w p.l1212r p.d1400h DNA binding RFX DNA binding Zinc finger KMT2C p.a51s p.d372v p.c1103* p.d2847fs p.t2671 p.d2847fs p.r4586h PHD/ RING DHHC/ PHD PHD FYR N
More informationNature Medicine doi: /nm.3957
Supplementary Fig. 1. p38 alternative activation, IL-21 expression, and T helper cell transcription factors in PDAC tissue. (a) Tissue microarrays of pancreatic tissue from 192 patients with pancreatic
More informationSupplementary Fig. 1. GPRC5A post-transcriptionally down-regulates EGFR expression. (a) Plot of the changes in steady state mrna levels versus
Supplementary Fig. 1. GPRC5A post-transcriptionally down-regulates EGFR expression. (a) Plot of the changes in steady state mrna levels versus changes in corresponding proteins between wild type and Gprc5a-/-
More informationp47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO
Supplementary Information p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO Yuri Shibata, Masaaki Oyama, Hiroko Kozuka-Hata, Xiao Han, Yuetsu Tanaka,
More informationSupplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the
Supplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the genome-wide methylation microarray data. Mean ± s.d.; Student
More informationFigure S1: Effects on haptotaxis are independent of effects on cell velocity A)
Supplemental Figures Figure S1: Effects on haptotaxis are independent of effects on cell velocity A) Velocity of MV D7 fibroblasts expressing different GFP-tagged Ena/VASP family proteins in the haptotaxis
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationSupplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with
Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with DMN Immunohistochemistry for hepcidin and H&E staining (left). qrt-pcr assays for hepcidin in the liver (right).
More informationSupplementary Information
Supplementary Information mediates STAT3 activation at retromer-positive structures to promote colitis and colitis-associated carcinogenesis Zhang et al. a b d e g h Rel. Luc. Act. Rel. mrna Rel. mrna
More informationNature Genetics: doi: /ng Supplementary Figure 1. HOX fusions enhance self-renewal capacity.
Supplementary Figure 1 HOX fusions enhance self-renewal capacity. Mouse bone marrow was transduced with a retrovirus carrying one of three HOX fusion genes or the empty mcherry reporter construct as described
More informationLentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression.
Supplementary Figure 1 Lentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression. a, Design for lentiviral combinatorial mirna expression and sensor constructs.
More informationRNA extraction, RT-PCR and real-time PCR. Total RNA were extracted using
Supplementary Information Materials and Methods RNA extraction, RT-PCR and real-time PCR. Total RNA were extracted using Trizol reagent (Invitrogen,Carlsbad, CA) according to the manufacturer's instructions.
More informationPrognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.
Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationSupplementary Information
Supplementary Information Figure S1. Int6 gene silencing efficiency. (A) Western Blot analysis of Int6 expression at different times after sirna transfection. Int6 expression is strongly silenced in Int6
More informationIn vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG)
In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG) 1 Dr Saeb Aliwaini 13/11/2015 Migration in vivo Primary tumors are responsible for only about 10%
More informationSupplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12
1 Supplementary Data Figure legends Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12 serum levels measured by multiplex ELISA (Luminex) in FL patients before
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationNature Genetics: doi: /ng Supplementary Figure 1. Phenotypic characterization of MES- and ADRN-type cells.
Supplementary Figure 1 Phenotypic characterization of MES- and ADRN-type cells. (a) Bright-field images showing cellular morphology of MES-type (691-MES, 700-MES, 717-MES) and ADRN-type (691-ADRN, 700-
More informationEffects of UBL5 knockdown on cell cycle distribution and sister chromatid cohesion
Supplementary Figure S1. Effects of UBL5 knockdown on cell cycle distribution and sister chromatid cohesion A. Representative examples of flow cytometry profiles of HeLa cells transfected with indicated
More informationTo analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma
To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma R. Zalazar, M. Páramo, M. Hernández, P. Domínguez, J.Etxano, P.García Barquín, H.Quiceno Arias,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in
More informationType of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
More informationDescription of Supplementary Files. File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables
Description of Supplementary Files File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables Supplementary Figure 1: (A), HCT116 IDH1-WT and IDH1-R132H cells were
More informationSupplementary Figure 1. mrna targets were found in exosomes and absent in free-floating supernatant. Serum exosomes and exosome-free supernatant were
Supplementary Figure 1. mrna targets were found in exosomes and absent in free-floating supernatant. Serum exosomes and exosome-free supernatant were separated via ultracentrifugation and lysed to analyze
More informationSupplementary Materials and Methods
Supplementary Materials and Methods Immunoblotting Immunoblot analysis was performed as described previously (1). Due to high-molecular weight of MUC4 (~ 950 kda) and MUC1 (~ 250 kda) proteins, electrophoresis
More informationm 6 A mrna methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer
SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41556-018-0174-4 In the format provided by the authors and unedited. m 6 A mrna methylation regulates AKT activity to promote the proliferation
More informationSupplementary Figure 1: Expression of NFAT proteins in Nfat2-deleted B cells (a+b) Protein expression of NFAT2 (a) and NFAT1 (b) in isolated splenic
Supplementary Figure 1: Expression of NFAT proteins in Nfat2-deleted B cells (a+b) Protein expression of NFAT2 (a) and NFAT1 (b) in isolated splenic B cells from WT Nfat2 +/+, TCL1 Nfat2 +/+ and TCL1 Nfat2
More informationSUPPLEMENTARY INFORMATION
doi: 10.1038/nature05732 SUPPLEMENTARY INFORMATION Supplemental Data Supplement Figure Legends Figure S1. RIG-I 2CARD undergo robust ubiquitination a, (top) At 48 h posttransfection with a GST, GST-RIG-I-2CARD
More informationSupplementary Online Content
Supplementary Online Content Jänne PA, van den Heuvel MM, Barlesi F, et al. Effect of selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant
More informationPharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Supplementary information for: Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma Rintaro Hashizume 1, Noemi Andor 2, Yuichiro Ihara 2, Robin Lerner 2, Haiyun
More informationS1 Appendix: Figs A G and Table A. b Normal Generalized Fraction 0.075
Aiello & Alter (216) PLoS One vol. 11 no. 1 e164546 S1 Appendix A-1 S1 Appendix: Figs A G and Table A a Tumor Generalized Fraction b Normal Generalized Fraction.25.5.75.25.5.75 1 53 4 59 2 58 8 57 3 48
More informationAP Statistics. Semester One Review Part 1 Chapters 1-5
AP Statistics Semester One Review Part 1 Chapters 1-5 AP Statistics Topics Describing Data Producing Data Probability Statistical Inference Describing Data Ch 1: Describing Data: Graphically and Numerically
More informationSupplementary Figure 1. Successful excision of genes from WBM lysates and
Supplementary Information: Supplementary Figure 1. Successful excision of genes from WBM lysates and survival of mice with different genotypes. (a) The proper excision of Pten, p110α, p110α and p110δ was
More informationfl/+ KRas;Atg5 fl/+ KRas;Atg5 fl/fl KRas;Atg5 fl/fl KRas;Atg5 Supplementary Figure 1. Gene set enrichment analyses. (a) (b)
KRas;At KRas;At KRas;At KRas;At a b Supplementary Figure 1. Gene set enrichment analyses. (a) GO gene sets (MSigDB v3. c5) enriched in KRas;Atg5 fl/+ as compared to KRas;Atg5 fl/fl tumors using gene set
More informationSupplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2
Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2 activity. Upper panel: Representative histograms for FACS
More informationSupplemental Table 1 Molecular Profile of the SCLC Cell Line Panel
Supplemental Table 1 Molecular Profile of the SCLC Cell Line Panel p53 RB Myc Cell Line Mutation A Mutation A Amplification B COR-L103 C p.y234c p.d584e L-Myc NCI-H526 p.s33_splice None N-Myc NCI-H1048
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationUniversity of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers
University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of
More informationSUPPLEMENTARY FIGURES: Supplementary Figure 1
SUPPLEMENTARY FIGURES: Supplementary Figure 1 Supplementary Figure 1. Glioblastoma 5hmC quantified by paired BS and oxbs treated DNA hybridized to Infinium DNA methylation arrays. Workflow depicts analytic
More informationSupplementary Materials and Methods
DD2 suppresses tumorigenicity of ovarian cancer cells by limiting cancer stem cell population Chunhua Han et al. Supplementary Materials and Methods Analysis of publicly available datasets: To analyze
More informationSUPPLEMENTARY FIGURES
SUPPLEMENTARY FIGURES Figure S1. Clinical significance of ZNF322A overexpression in Caucasian lung cancer patients. (A) Representative immunohistochemistry images of ZNF322A protein expression in tissue
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/2/1/ra81/dc1 Supplementary Materials for Delivery of MicroRNA-126 by Apoptotic Bodies Induces CXCL12- Dependent Vascular Protection Alma Zernecke,* Kiril Bidzhekov,
More informationBreeding scheme, transgenes, histological analysis and site distribution of SB-mutagenized osteosarcoma.
Supplementary Figure 1 Breeding scheme, transgenes, histological analysis and site distribution of SB-mutagenized osteosarcoma. (a) Breeding scheme. R26-LSL-SB11 homozygous mice were bred to Trp53 LSL-R270H/+
More information<10. IL-1β IL-6 TNF + _ TGF-β + IL-23
3 ns 25 ns 2 IL-17 (pg/ml) 15 1 ns ns 5 IL-1β IL-6 TNF
More informationSUPPLEMENTARY FIGURES AND TABLE
SUPPLEMENTARY FIGURES AND TABLE Supplementary Figure S1: Characterization of IRE1α mutants. A. U87-LUC cells were transduced with the lentiviral vector containing the GFP sequence (U87-LUC Tet-ON GFP).
More informationSOPten flox/flox (KO) Pten flox/flox (WT) flox allele 6.0 kb. Pten. Actin. ! allele 2.3 kb. Supplementary Figure S1. Yanagi, et al.
s1 A Pten flox/flox () SOPten flox/flox () flox allele 6. kb B Pten flox/flox () SOPten flox/flox () Pten Actin! allele 2.3 kb Supplementary Figure S1. Yanagi, et al. A B BrdU BrdU positive cells ( ) 3
More informationSupplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well
Supplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well plate at cell densities ranging from 25-225 cells in
More informationSupplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as
Supplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as well as their downstream effectors across a panel of ESCC
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationunderlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The
Supplementary Figures Figure S1. Patient cohorts and study design. To define and interrogate the genetic alterations underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The
More informationHCC1937 is the HCC1937-pcDNA3 cell line, which was derived from a breast cancer with a mutation
SUPPLEMENTARY INFORMATION Materials and Methods Human cell lines and culture conditions HCC1937 is the HCC1937-pcDNA3 cell line, which was derived from a breast cancer with a mutation in exon 20 of BRCA1
More informationA clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
More informationTechnology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10866 a b 1 2 3 4 5 6 7 Match No Match 1 2 3 4 5 6 7 Turcan et al. Supplementary Fig.1 Concepts mapping H3K27 targets in EF CBX8 targets in EF H3K27 targets in ES SUZ12 targets in ES
More informationSupplementary Figure S1. PTPN2 levels are not altered in proliferating CD8+ T cells. Lymph node (LN) CD8+ T cells from C57BL/6 mice were stained with
Supplementary Figure S1. PTPN2 levels are not altered in proliferating CD8+ T cells. Lymph node (LN) CD8+ T cells from C57BL/6 mice were stained with CFSE and stimulated with plate-bound α-cd3ε (10µg/ml)
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationSupplementary Information Titles Journal: Nature Medicine
Supplementary Information Titles Journal: Nature Medicine Article Title: Corresponding Author: Supplementary Item & Number Supplementary Fig.1 Fig.2 Fig.3 Fig.4 Fig.5 Fig.6 Fig.7 Fig.8 Fig.9 Fig. Fig.11
More informationSupplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs.
Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs. (a) CNA analysis of expression microarray data obtained from 15 tumors in the SV40Tag
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationSUPPLEMENTARY INFORMATION
DOI: 10.1038/ncb2607 Figure S1 Elf5 loss promotes EMT in mammary epithelium while Elf5 overexpression inhibits TGFβ induced EMT. (a, c) Different confocal slices through the Z stack image. (b, d) 3D rendering
More informationX P. Supplementary Figure 1. Nature Medicine: doi: /nm Nilotinib LSK LT-HSC. Cytoplasm. Cytoplasm. Nucleus. Nucleus
a b c Supplementary Figure 1 c-kit-apc-eflu780 Lin-FITC Flt3-Linc-Kit-APC-eflu780 LSK Sca-1-PE-Cy7 d e f CD48-APC LT-HSC CD150-PerCP-cy5.5 g h i j Cytoplasm RCC1 X Exp 5 mir 126 SPRED1 SPRED1 RAN P SPRED1
More informationSupplementary Figure 1
Supplementary Figure 1 Asymmetrical function of 5p and 3p arms of mir-181 and mir-30 families and mir-142 and mir-154. (a) Control experiments using mirna sensor vector and empty pri-mirna overexpression
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Pan-cancer analysis of global and local DNA methylation variation a) Variations in global DNA methylation are shown as measured by averaging the genome-wide
More informationNature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases.
Supplementary Figure 1 Somatic coding mutations identified by WES/WGS for 83 ATL cases. (a) The percentage of targeted bases covered by at least 2, 10, 20 and 30 sequencing reads (top) and average read
More informationUnderstandable Statistics
Understandable Statistics correlated to the Advanced Placement Program Course Description for Statistics Prepared for Alabama CC2 6/2003 2003 Understandable Statistics 2003 correlated to the Advanced Placement
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationSupplementary Figure S1
Supplementary Figure S1 Supplementary Figure S1. PARP localization patterns using GFP-PARP and PARP-specific antibody libraries GFP-PARP localization in non-fixed (A) and formaldehyde fixed (B) GFP-PARPx
More information(a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable
Supplementary Figure 1. Frameshift (FS) mutation in UVRAG. (a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable A 10 DNA repeat, generating a premature stop codon
More informationiplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers).
Supplementary Materials Supplementary Methods iplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers). IDH1 R132H and R132L Forward:
More informationSupplemental Data Macrophage Migration Inhibitory Factor MIF Interferes with the Rb-E2F Pathway
Supplemental Data Macrophage Migration Inhibitory Factor MIF Interferes with the Rb-E2F Pathway S1 Oleksi Petrenko and Ute M. Moll Figure S1. MIF-Deficient Cells Have Reduced Transforming Ability (A) Soft
More informationType of file: PDF Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Title of file for HTML: Supplementary Information Description: Supplementary Figures Type of file: MOV Title of file for HTML: Supplementary Movie 1 Description: NLRP3 is moving along
More informationNature Medicine: doi: /nm.4078
Supplementary Figure 1. Cetuximab induces ER stress response in DiFi cells. (a) Scheme of SILAC proteome. (b) MS-base read out of SILAC experiment. The histogram of log 2 -transformed normalized H/L ratios
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationPUMA gene transfection can enhance the sensitivity of epirubicin-induced apoptosis of MCF-7 breast cancer cells
PUMA gene transfection can enhance the sensitivity of epirubicin-induced apoptosis of MCF-7 breast cancer cells C.-G. Sun 1 *, J. Zhuang 1 *, W.-J. Teng 1, Z. Wang 2 and S.-S. Du 3 1 Department of Oncology,
More informationSUPPLEMENTAL EXPERIMENTAL PROCEDURES
SUPPLEMENTAL EXPERIMENTAL PROCEDURES Crystal violet assay Cells were seeded in 24-well plates and cultured in media supplemented with % FBS for 7 days. Media were then removed, plates were briefly washed
More informationNature Immunology: doi: /ni Supplementary Figure 1. DNA-methylation machinery is essential for silencing of Cd4 in cytotoxic T cells.
Supplementary Figure 1 DNA-methylation machinery is essential for silencing of Cd4 in cytotoxic T cells. (a) Scheme for the retroviral shrna screen. (b) Histogram showing CD4 expression (MFI) in WT cytotoxic
More informationIntroduction to Gene Sets Analysis
Introduction to Svitlana Tyekucheva Dana-Farber Cancer Institute May 15, 2012 Introduction Various measurements: gene expression, copy number variation, methylation status, mutation profile, etc. Main
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More information(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)
Supplementary Figure 1. Functional enrichment analyses of secretomic proteins. (a) Significant biological processes (upper panel) and disease biomarkers (lower panel) 2 involved by hrab37-mediated secretory
More informationSupplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III
Supplementary Materials: Supplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III patient samples. Genomic DNA samples extracted from punch biopsies from either FFPE or frozen tumor
More information